Application of dicarbamin in treatment of patients by a chronic hepatitis C
Abstract
Aim of investigation. Studying of clinical and laboratory efficacy of dicarbamin as hematoprotector in patients with chronic hepatitis C (CHC) with 1b virus genotype at combined antiviral therapy (AVT) by pegilated interferons in combination to ribavirin.
Material and methods. Overall 110 patients with CHC (genotype 1b) with WBC count from 3,9 to 3,0×109/l and neutrophile count from 2,0 to 1,5×109/l according to TBC were under surveillance. Patients were divided to comparable groups by gender and age in relation to the treatment mode: the 1-st group (n=52) received peginterferon α2b + ribavirin, the 2-nd group (n=58) – peginterferon α2b + ribavirin + dicarbamin 100 mg od for 21 day. Subsequently dicarbamin was prescribed to all patients in the similar mode for 3 months.
Results. At combined AVT no undesirable effects as decrease of total leukocyte and neutrophile count were revealed. In the 1-st group leukopenia was observed from the 4-th week of treatment in 71%, neutropenia – in 69% of patients, similar parameters kept significantly lower during the whole course of treatment in comparison to the 2-nd group that resulted in dose decline of peginterferon α2b in 26,9% and cancellation of AVT in 9,6% of patients. At patients of the 2-nd group leukopenia was marked in 35%, neutropenia – in 46% of cases. No significant reduction of leukocyte and neutrophile count which could cause correction of dose or cessation of AVT has not been registered in this group.
Conclusions. Application of dicarbamin at combined antiviral therapy of CHC results in elevation of leukocyte and neutrophile count in the blood and allows to carry out treatment without dose decline and cancellation of peginterferon. High tolerability of AVT in CHC patients at application of suggested mode of treatment (peginterferon α2b, ribavirin and dicarbamin) was revealed.
About the Authors
D. Yu. KonstantinovRussian Federation
Ye. A. Konstantinova
Russian Federation
L. L. Popova
Russian Federation
E. A. Strebkova
Russian Federation
A. A. Suzdaltsev
Russian Federation
References
1. Абдурахманов Д.Т. Перспективы в лечении хронического гепатита С // Клиническая гепатология. – 2010. – № 3. – С. 3–11.
2. Ивашкин В.Т., Лобзин Ю.В., Сторожаков Г.И. и др. Эффективность и безопасность 48-ми недельной терапии пегинтерфероном α-2а и рибавирином у первичных больных хроническим гепатитом С // Клин. фармакол. терапия. – 2007. – Т. 16, № 1. – С. 1–5.
3. Fried M.W., Shiftman M., Reddy R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection // N. Engl. J. Med. – 2002. – Vol. 347. – P. 975–982.
4. Manns M., McHutchison J., Gordon S. et al. Kinetic of virological response during Peg-IFNS in chronic hepatitis C // J. Hepatol. – 2004. – Vol. 40 (suppl. 1). – P. 490.
5. Гепатиты. Рациональная диагностика и терапия / Под ред. Михаэля Фукса; пер. с нем. под ред. А.О. Буеверова. – М.: ГЭОТАР-Медиа, 2010. – 240 с.
6. Lindsay K.L., Trepo С., Heintges Т. et al. A randomized, double-blind trial comparing pegylated interferon a-2b to interferon a-2b as initial treatment for chronic hepatitis C // Hepatology. – 2001. – Vol. 34, N 2. – P. 395–403.
7. Fontana R.J., Walsh J., Moyer C.A. et al. High dose interfere on alpha 2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial // J. Clin. Gastroenterol. – 2002. – Vol. 34, N 2. – P. 177–182.
8. Manns M., McHutchinson J.G., Gordon S. et al. Peginterferon alpha 2b plus ribavirin compared with interferon alpha 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial // Lancet. – 2001. – Vol. 358. – P. 958–965.
9. Viscoli С. The evolution of the empirical management of fever and neutropenia in cancer patients // J. Antimicrob. Chemother. – 1998. – Vol. 41 (suppl. D). – P. 65–80.
10. Hagashi J., Sakai K., Tada S. et al. Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C // J. Gastroenterol. Hepatol. – 1996. – Vol. 11. – P. 1012–1015.
11. Fukuda A., Kobayashi H., Teramura K. et al. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis С patients // Cytokines Cell. Mol. Ther. – 2000. – Vol. 6. – P. 149–154.
12. Carreno V., Martin J., PardoM. et al. Randomized controlled trial of recombinant human granulocytemacrophage colony-stimulating factor for the treatment of chronic hepatitis C // Citokine. – 2000. – Vol. 12. – P. 165–170.
Review
For citations:
Konstantinov D.Yu., Konstantinova Ye.A., Popova L.L., Strebkova E.A., Suzdaltsev A.A. Application of dicarbamin in treatment of patients by a chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(5):58-63. (In Russ.)
Views:
66
Email this article 
